From Concept to Medicine - A Comprehensive Drug Development Journey

• 21 Atorvastatin (S24E21)

  Nearly 45% of all deaths from non-communicable diseases worldwide are caused by cardiovascular disease—a staggering reality that frames the story of atorvastatin, better known as Lipitor. In this episode of From Concept to Medicine’s Periodic Table of Medicine, we trace the full journey of one of the world’s most influential drugs.From the centuries-long unraveling of cholesterol’s chemistry, through the serendipitous discovery of early statins in the 1970s, to Pfizer’s launch of atorvastatin in 1997, this episode dives deep into the science, medicine, and controversy behind a blockbuster. We explore how atorvastatin works to lower LDL cholesterol, its clinical uses from common hyperlipidemia to genetic conditions, and its role in reducing heart attack and stroke risk. Along the way, we unpack the intricacies of pharmacology, drug interactions, and safety considerations—while also pulling back the curtain on its complex manufacturing, regulatory battles, and high-stakes patent wars.But atorvastatin’s impact goes beyond the lab and the clinic. We look at its cultural imprint, from billion-dollar sales and household recognition to heated debates over marketing ethics and the shift to affordable generics. What emerges is a sweeping view of how one molecule reshaped global health, transformed an industry, and sparked questions about access, innovation, and trust in medicine.

  --------  

  26:10

  --------

  26:10
• 185 - Episode 5 - Good Documentation Practices (GDP) in Medical Devices - The ALCOA+ Standard (S25E5)

  In this compelling Deep Dive, we explore the unglamorous but absolutely essential world of medical device documentation. From design inception to post-market surveillance, documentation isn't just red tape—it's the backbone of compliance, traceability, and patient safety. This episode introduces listeners to the U.S. FDA's regulatory foundation in 21 CFR Part 820 and shines a spotlight on ALCOA+ principles: the industry gold standard for ensuring that every action, every test, and every result is accurate, trustworthy, and audit-ready. Through clear examples and engaging conversation, the episode maps how documentation supports every phase of a device's life, from design through manufacturing to corrective actions and recalls.Listeners are guided through the three cornerstone documents of medical device quality—Design History File (DHF), Device Master Record (DMR), and Device History Record (DHR)—with an emphasis on how each connects design intent to execution and oversight. The narrative expands to include digital documentation, introducing 21 CFR Part 11 requirements for electronic records and audit trails. With real-world stakes, like product holds due to missing signatures, the episode demonstrates how documentation failures can halt entire product lines. Most importantly, it reframes GDP as a cultural mindset—a proactive approach to quality rather than a bureaucratic burden. It’s a must-hear for anyone looking to understand the DNA of device quality systems.

  --------  

  13:51

  --------

  13:51
• 20 Liraglutide (S24E20)

  In this expansive episode of The Deep Dive, we explore the full lifecycle of liraglutide, a first-generation GLP-1 receptor agonist that helped redefine how we treat both type 2 diabetes and obesity. From the early 20th-century discovery of incretin hormones to the molecular engineering breakthroughs that enabled liraglutide’s once-daily dosing, the episode traces the drug’s scientific and clinical journey in vivid detail. We break down its mechanism of action—including glucose-dependent insulin secretion and appetite regulation through central satiety pathways—as well as its pharmacokinetic properties, such as albumin binding and extended half-life. Clinical trials are explored in depth, with attention to both its glycemic benefits and its weight loss efficacy in diverse populations, including those with prediabetes, sleep apnea, and post-bariatric weight regain. Listeners will also hear about real-world considerations like dosing schedules, combination regimens, and discontinuation benchmarks.Beyond the clinic, the episode examines liraglutide’s high-tech peptide manufacturing process, its regulatory milestones and REMS-mandated safety messaging, and the legal controversies that culminated in a $58 million U.S. federal settlement. We evaluate its economic footprint in the diabetes and obesity markets, including the implications of the first generic approval in 2024. Cultural impacts are explored as well, from shifting societal attitudes toward obesity treatment to access inequities and emerging stigma against pharmacologic weight loss. We conclude with an honest look at newer competitors like semaglutide and what the future might hold for liraglutide as part of a changing treatment paradigm. This episode offers a rare 360-degree view into one of the most influential metabolic therapies of the 21st century.

  --------  

  27:14

  --------

  27:14
• 18 Pioglitazone (S24E18)

  In this compelling episode of The Deep Dive, we explore the multifaceted story of pioglitazone, a thiazolidinedione (TZD) insulin sensitizer used to treat type 2 diabetes. From its origins in 1980s Japan to its development as a follow-up to troglitazone—the first but short-lived TZD—we trace how pioglitazone emerged as a promising therapy that targets insulin resistance at the genetic level through PPARγ activation. The episode explains its mechanism of action, pharmacokinetics, and clinical utility in lowering HbA1c and improving lipid profiles. We also explore its nuanced cardiovascular profile, highlighting major trials like PROactive and IRIS, which revealed potential heart and stroke benefits despite mixed overall results. Additional research into pioglitazone’s potential in Alzheimer’s, opioid addiction, and inflammatory disorders reflects its surprising reach beyond diabetes care.Listeners will also hear about pioglitazone’s complex regulatory and legal history, especially surrounding the long-running controversy over bladder cancer risk, which prompted warnings, international suspensions, and over $2 billion in legal settlements. The episode breaks down manufacturing processes, CYP enzyme interactions, and post-patent generics, illustrating its shift from branded blockbuster to cost-effective generic therapy. Pioglitazone's economic impact is evaluated alongside newer diabetes drugs like SGLT2 inhibitors and GLP-1 receptor agonists that offer clearer cardiometabolic benefits. Finally, we reflect on pioglitazone’s cultural and clinical legacy—how it changed the conversation around insulin resistance, spurred caution around long-term drug safety, and remains a part of the evolving therapeutic landscape. This episode equips listeners to think critically about risk-benefit decisions in modern diabetes treatment.

  --------  

  33:15

  --------

  33:15
• 17 Sitagliptin (S24E17)

  In this episode of The Deep Dive, we explore the full lifecycle of sitagliptin, the first oral DPP-4 inhibitor to revolutionize type 2 diabetes management. Starting with its scientific origins in the 1990s, the episode traces how researchers discovered the role of incretin hormones and developed sitagliptin to preserve their glucose-lowering effects. Listeners will learn how sitagliptin works selectively to boost insulin secretion and suppress glucagon—without causing significant hypoglycemia when used alone. We break down its pharmacokinetics, renal clearance pathways, and critical dose adjustments for patients with impaired kidney function. The conversation also unpacks clinical applications, real-world efficacy, weight neutrality, and how the drug performs in combination with metformin or insulin therapies.Beyond the clinic, the episode delves into how sitagliptin is manufactured, its asymmetric hydrogenation synthesis, and how Merck scaled it into a global blockbuster under the Januvia and Janumet brands. We examine its regulatory approval history, long-term safety signals—including concerns over pancreatitis and rare skin reactions—and Merck’s strategic use of salt form patents to extend exclusivity in the U.S. until 2026. Global market dynamics are unpacked, with generics gaining traction in Europe and Asia while the U.S. market still holds due to delayed competition. Sitagliptin's cultural and economic footprint is also discussed—from adherence advantages to its role in shaping treatment guidelines and access initiatives. With newer classes like GLP-1 agonists and SGLT2 inhibitors emerging, the episode closes by asking: what will be the future place of sitagliptin in a rapidly evolving diabetes landscape?

  --------  

  16:28

  --------

  16:28

Altri podcast di Scolastico

Podcast di tendenza in Scolastico

Su From Concept to Medicine - A Comprehensive Drug Development Journey

From Concept to Medicine - A Comprehensive Drug Development Journey: Podcast correlati